Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company will license EGFR and cMet inhibitors from Celyn.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
